Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1960 1
1962 1
1964 3
1965 1
1966 5
1967 4
1969 1
1970 4
1971 8
1972 4
1973 1
1974 1
1975 8
1976 2
1977 2
1978 3
1979 4
1980 6
1982 5
1983 5
1984 1
1985 5
1986 8
1987 9
1988 7
1989 7
1990 3
1991 8
1992 3
1993 13
1994 10
1995 17
1996 13
1997 8
1998 15
1999 15
2000 16
2001 22
2002 16
2003 17
2004 17
2005 11
2006 21
2007 29
2008 15
2009 35
2010 20
2011 31
2012 46
2013 38
2014 47
2015 57
2016 41
2017 44
2018 54
2019 50
2020 46
2021 68
2022 45
2023 44
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

982 results

Results by year

Filters applied: . Clear all
Page 1
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T. Mikami H, et al. Among authors: azuma y. Cancer Immunol Res. 2024 Apr 1:OF1-OF12. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38563577
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T. Mikami H, et al. Among authors: azuma y. Cancer Immunol Res. 2024 Mar 20. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38558120
982 results